Citations

Showing 10 of 108081 citations.

Advances Afoot in Microbiology
Patel, Robin , Karon, Brad S. , Patel, Robin

Mayo Clinic

Journal of Clinical Microbiology | May 25, 2017 | Volume: 55 | Issue: 7 | Pages: 1984-1988

10.1128/jcm.00664-17 | PMID 28539341 Get It

ABSTRACT In 2016, the American Academy of Microbiology convened a colloquium to examine point-of-care (POC) microbiology testing and to evaluate its effects on clinical microbiology. Colloquium participants included representatives from clinical microbiology laboratories, industry, and the government, who together made recommendations regarding the implementation, oversight, and evaluation of POC microbiology testing. The colloquium report is timely and well written (V. Dolen et al., Changing Diagnostic Paradigms for Microbiology , 2017, https://www.asm.org/index.php/colloquium-reports/item/6421-changing-diagnostic-paradigms-for-microbiology?utm_source=Commentary&utm_medium=referral&utm_campaign=diagnostics ). Emerging POC microbiology tests, especially nucleic acid amplification tests, have the potential to advance medical care.
Enhanced Recovery Program and Length of Stay After Laparotomy on a Gynecologic Oncology Service: A Randomized Controlled Trial
Nelson, Gregg , Ramírez, Pedro T. , Ljungqvist, Olle , Dowdy, Sean C. , Nelson, Gregg S

Mayo Clinic

Obstetrics & Gynecology | May 24, 2017 | Volume: 129 | Issue: 6 | Pages: 1139-1139

10.1097/aog.0000000000002083 | PMID 28538481 Get It

Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure–Lowering Effects of Latanoprost
Roddy, Gavin W. , Viker, Kimberly, Winkler, Nelson S., Bahler, Cindy K., Holman, Bradley H., Sheikh‐Hamad, David , Chowdhury, Uttio Roy, Fautsch, Michael P. , Viker, Kimberly B, Roy Chowdhury, Uttio, Stamer, William Daniel

Mayo Clinic

Investigative Opthalmology & Visual Science | May 24, 2017 | Volume: 58 | Issue: 5 | Pages: 2715

10.1167/iovs.16-21004 | PMID 28538979 Get It

Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists
George, Tracy I. , Tworek, Joseph A., Thomas, Nicole , Fatheree, Lisa A., Souers, Rhona J., Nakhleh, Raouf E. , Arber, Daniel A. , George, Tracy I

Mayo Clinic

Archives of Pathology & Laboratory Medicine | May 24, 2017 | Volume: 141 | Issue: 8 | Pages: 1101-1106

10.5858/arpa.2016-0398-cp | PMID 28537804 Get It

Context.— The classification and prognosis determination in acute leukemia (AL) are complex and it is unclear what testing is being performed in practice. Objective.— To survey physicians describing their current practice of test ordering in the diagnosis of AL. Design.— In anticipation of a guideline by the College of American Pathologists (CAP) and the American Society for Hematology on laboratory testing needed for the initial workup of AL, a baseline survey was designed by an expert panel from CAP. Members of professional societies were asked to describe their current practice of test ordering. Results.— Two hundred ninety-four responses were received with 258 respondents analyzed after the first qualifying survey question regarding initial diagnosis of AL. One hundred seventy-six of 249 respondents (70.7%) were board-certified hematopathologists. Flow cytometry and karyotype analysis were routinely performed for acute myeloid leukemia (AML) (99.1% [232 of 234] and 96.2% [225 of 234], respectively) and acute lymphoblastic leukemia (ALL) (98.3% [229 of 233] and 96.6% [225 of 233], respectively). In addition, fluorescence in situ hybridization studies were routinely performed by 81.2% (190 of 234) of respondents for AML and 85.0% (198 of 233) of respondents for ALL; other molecular studies were performed by 78.2% (183) for AML and 54.9% (128) for ALL; immunohistochemistry by 44.9% (105) for AML and 47.6% (111) for ALL; and cytochemistry by 24.8% (58) for AML and 14.2% (33) for ALL. Conclusions.— While flow cytometry and karyotyping are routinely reported as being performed for the diagnosis of AL, there is marked variation in the reporting of testing patterns for other genetic studies, immunohistochemistry, and cytochemistry.
A Versatile Protocol for Studying Calvarial Bone Defect Healing in a Mouse Model
Samsonraj, Rebekah M. , Dudakovic, Amel , Zan, Pengfei, Pichurin, Oksana , Cool, Simon M. , Wijnen, André J. van , van Wijnen, Andre J, van Wijnen, Andre J

Mayo Clinic

Tissue Engineering Part C: Methods | May 24, 2017 | Volume: 23 | Issue: 11 | Pages: 686-693

10.1089/ten.tec.2017.0205 | PMID 28537529 Get It

Aneurysm Morphology and Prediction of Rupture: An International Study of Unruptured Intracranial Aneurysms Analysis
Brown, Robert D., Torner, James C., Fargen, Kyle M , Raghavan, Madhavan L. , Piepgras, David G., Meissner, Irene, Investigators, on behalf of the International Study of Unruptured Intracranial Aneurysms, Torner, James C. , Mocco, J , Capuano, Ana Werneck , Huston, John , Investigators, on behalf of the International Study of Unruptured Intracranial Aneurysms, Fargen, Kyle M

Mayo Clinic

Neurosurgery | May 24, 2017 | Volume: 82 | Issue: 4 | Pages: 491-496

10.1093/neuros/nyx226 | PMID 28605486 Get It

Abstract BACKGROUND There are conflicting data between natural history studies suggesting a very low risk of rupture for small, unruptured intracranial aneurysms and retrospective studies that have identified a much higher frequency of small, ruptured aneurysms than expected. OBJECTIVE To use the prospective International Study of Unruptured Intracranial Aneurysms cohort to identify morphological characteristics predictive of unruptured intracranial aneurysm rupture. METHODS A case-control design was used to analyze morphological characteristics associated with aneurysm rupture in the International Study of Unruptured Intracranial Aneurysms database. Fifty-seven patients with ruptured aneurysms during follow-up were matched (by size and location) with 198 patients with unruptured intracranial aneurysms without rupture during follow-up. Twelve morphological metrics were measured from cerebral angiograms in a blinded fashion. RESULTS Perpendicular height ( P = .008) and size ratio (ratio of maximum diameter to the parent vessel diameter; P = .01) were predictors of aneurysm rupture on univariate analysis. Aspect ratio, daughter sacs, multiple lobes, aneurysm angle, neck diameter, parent vessel diameter, and calculated aneurysm volume were not statistically significant predictors of rupture. On multivariate analysis, perpendicular height was the only significant predictor of rupture (Chi-square 7.1, P -value .008). CONCLUSION This study underscores the importance of other morphological factors, such as perpendicular height and size ratio, that may influence unruptured intracranial aneurysm rupture risk in addition to greatest diameter and anterior vs posterior location.
Tumor Progression Following Petroclival Meningioma Subtotal Resection: A Volumetric Study
Hunter, Jacob B. , O’Connell, Brendan P., Carlson, Matthew L. , Chambless, Lola, Yawn, Robert J. , Mistry, Akshitkumar M. , Thompson, Reid C., Weaver, Kyle D., Wanna, George B. , Wang, Ray , Hunter, Jacob B

Mayo Clinic

Operative Neurosurgery | May 24, 2017 | Volume: 14 | Issue: 3 | Pages: 215-223

10.1093/ons/opx098 | PMID 28541487 Get It

Abstract BACKGROUND One study has investigated postoperative growth rates following subtotal resection of petroclival meningiomas utilizing linear measurements, which are insensitive to the multidimensional complex growth of meningiomas, to estimate tumor volume. OBJECTIVE To describe petroclival meningioma growth patterns following less-than-complete resection utilizing volumetric analysis and to identify variables associated with tumor progression. METHODS Patients with surgically resected WHO grade I petroclival meningiomas were retrospectively reviewed (1999-2015). Image analysis software was utilized to perform volumetric analyses of tumor size and growth on serial MRI studies. The impact of preoperative and postoperative variables on tumor growth after subtotal resection was analyzed. An increase in tumor volume of at least 20% was defined as “tumor growth.” RESULTS Twenty-three patients had immediate preoperative and serial postoperative MRI studies available for review. The mean preoperative tumor volume was 20.9 cm 3 (range 0.4-54.6). The mean extent of resection was 75.5% (range 31.5%-100.0%). At a mean follow-up of 24.8 mo, 12 tumors (66.7%) exhibited radiological tumor growth, while 6 tumors did not change in size. The median annual volumetric growth rate was 2.82 cm 3 /yr (range –0.34 to 10.1). Extent of resection and immediate postoperative tumor volume were significantly correlated with the annual volumetric growth rate following resection. At last follow-up, 3 (13%) patients required further intervention. CONCLUSION The majority of petroclival meningiomas exhibit growth following subtotal resection. Extent of resection is strongly associated with risk for disease progression following surgery.
Discordance Between Physician Assessment and Patient-Reported Depressive Symptoms in Parkinson Disease
Lachner, Christian , Armstrong, Melissa J. , Gruber‐Baldini, Ann L. , Rezvani, Zahra , Reich, Stephen G. , Fishman, Paul S., Salazar, Richard, Shulman, Lisa , Armstrong, Melissa J

Mayo Clinic

Journal of Geriatric Psychiatry and Neurology | May 24, 2017 | Volume: 30 | Issue: 4 | Pages: 191-195

10.1177/0891988717710335 | PMID 28535723 Get It

Objective: To assess concordance between physician assessment and patient-reported symptoms when screening for depression in Parkinson disease (dPD). Background: Depression in Parkinson disease is highly prevalent (∼40%) and has a significant impact on quality of life and disability, yet physician recognition and treatment remain inadequate. Methods: One thousand seventy-six patients with PD completed the Brief Symptom Inventory-18 (BSI-18), a screening questionnaire for psychiatric symptoms, which was compared to item #3 (depression) on the Unified Parkinson’s Disease Rating Scale (UPDRS). Results: The mean BSI-18 depression score was 51.4 (9.7). Of the 170 (16%) patients screening positive for dPD on the BSI-18, 104 (61%) were not recognized as depressed by neurologists on the UPDRS. Factors associated with lower neurologist recognition included male gender, better mental health quality of life, and lack of antidepressant use. Conclusion: More than 60% of patients screening positive for depression on self-report were not recognized by neurologists on the UPDRS. A patient-reported screening tool for depression may improve recognition and management of dPD.
Cost of Alteplase Has More Than Doubled Over the Past Decade
Kleindorfer, Dawn , Demaerschalk, Bart, Saver, Jeffrey, Broderick, Joseph P. , Demaerschalk, Bart M. , Saver, Jeffrey L.

Mayo Clinic

Stroke | May 24, 2017 | Volume: 48 | Issue: 7 | Pages: 2000-2002

10.1161/strokeaha.116.015822 | PMID 28536176 Get It

Background and Purpose— Intravenous alteplase (tissue-type plasminogen activator) has been shown to be cost-effective because of savings in long-term disability. In October of 2005, an increased DRG payment to hospitals for alteplase-treated stroke patients was introduced. We sought to describe the trends in the cost of alteplase over time, in comparison to trends in hospital reimbursement in the United States. Methods— Using publicly available information on the Centers for Medicare and Medicaid Services (CMS) website ( www.cms.gov ), we obtained CMS quarterly payment amounts between January 1, 2005, and October 1, 2014, for alteplase, listed as alteplase recombinant, per mg. CMS payment amounts are the manufacturer’s average sales price+6% until April 2014, when it was lowered to +4.3%. Estimates for DRG base payments were calculated within the Medicare Provider and Analysis Review (MEDPAR) for fiscal years 2006 (DRG 559) and 2013 (MS DRGs 61, 62, and 63) as (DRG relative weights)×(standardized operating and capital amount). The consumer price index was also queried for all prescription drugs, urban areas, during the same study period as reference. Results— The CMS payment amount for alteplase per milligram was $30.50 in January 2005 and $64.30 in October 2014. Trends in the CMS payment amounts for alteplase increased by 111% between 2005 and 2014. The consumer price index for all prescription drugs increased by 30.2% in the same time frame. The base payment for alteplase-treated stroke admissions was $11 173 in 2006 and $12 064 in 2013, an 8% increase. Conclusions— We found a striking increase in the cost of alteplase over the last decade, with a 100 mg vial now with a CMS payment of ≈$6400, a >100% increase over 10 years. During the same time frame, the DRG base payment to hospitals increased by only 8%, and alteplase cost increased from 27% of the payment in 2006 to 53% in 2013. Researchers and stroke physicians should be aware of these changes in drug costs and their impact on cost-effectiveness analyses.
The Birkett Lecture: Avoiding the unhappy patient: The ABCs of rapport building
Kern, Eugene B. , Kern, Eugene Barton

Mayo Clinic

The Laryngoscope | May 24, 2017 | Volume: 127 | Issue: 11 | Pages: 2517-2521

10.1002/lary.26657 | PMID 28543001 Get It